These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27052634)

  • 1. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
    Sun W; Zeng C; Liao L; Chen J; Wang Y
    Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels.
    Zhang JP; Wang N; Xing XY; Yang ZJ; Wang X; Yang WY
    J Diabetes; 2016 Jul; 8(4):559-67. PubMed ID: 26331290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial.
    Zhang J; Wang N; Xing X; Yang Z; Wang X; Yang W
    Curr Med Res Opin; 2016; 32(4):713-9. PubMed ID: 26714411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
    Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
    Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
    Yang W; Liu J; Shan Z; Tian H; Zhou Z; Ji Q; Weng J; Jia W; Lu J; Liu J; Xu Y; Yang Z; Chen W
    Lancet Diabetes Endocrinol; 2014 Jan; 2(1):46-55. PubMed ID: 24622668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
    Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV
    Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary analysis of newly diagnosed type 2 diabetes subgroups and treatment responses in the MARCH cohort.
    Wang W; Li X; Chen F; Wei R; Chen Z; Li J; Qiao J; Pan Q; Yang W; Guo L
    Diabetes Metab Syndr; 2024 Jan; 18(1):102936. PubMed ID: 38171152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
    Halimi S; Le Berre MA; Grangé V
    Diabetes Res Clin Pract; 2000 Sep; 50(1):49-56. PubMed ID: 10936668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study.
    Mo D; Liu S; Ma H; Tian H; Yu H; Zhang X; Tong N; Liao J; Ren Y
    Drug Des Devel Ther; 2019; 13():2769-2776. PubMed ID: 31496653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes.
    Fu J; Liu J; Xu Y; Yang N; Yang W; Wang G
    Endocr J; 2019 May; 66(5):443-450. PubMed ID: 30944269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes mellitus patients in China.
    Zhang R; Zhao Q; Li R
    BMC Pharmacol Toxicol; 2022 Oct; 23(1):79. PubMed ID: 36258236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin.
    Phillips P; Karrasch J; Scott R; Wilson D; Moses R
    Diabetes Care; 2003 Feb; 26(2):269-73. PubMed ID: 12547847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Metformin-sulfonylurea and Metformin-acarbose Combination Therapies on Glycemic Outcomes: A Retrospective Cohort Study.
    Wafa W; Septini R; Sauriasari R
    Curr Diabetes Rev; 2022; 18(7):e031121197656. PubMed ID: 34732117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
    Hoffmann J; Spengler M
    Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
    Wang N; Zhang JP; Xing XY; Yang ZJ; Zhang B; Wang X; Yang WY
    J Diabetes; 2017 Aug; 9(8):728-737. PubMed ID: 27717194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.